Cite
HARVARD Citation
Pearl, M. et al. (2022). Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients. Clinical transplantation. 36 (8), p. n/a. [Online].